CTN-0048-A-1: Pharmacogenetics of Buprenorphine/Naltrexone for Cocaine Dependence in the CURB Study

David A. Nielsen, PhD
Co-Lead Investigator
Baylor College of Medicine, Texas

Thomas R. Kosten, MD
Co-Lead Investigator
Baylor College of Medicine, Texas

This study aims to test whether genetic markers in the mu, kappa, and nociceptin/orphanin FQ, OPRL1 receptors are associated with the efficacy of buprenorphine and naltrexone (BUP/NTX) for individuals with cocaine use disorder. Investigators hypothesize that patients with the functional mu polymorphism of OPRM1, rs1799971, A118G, which is non-synonymous Asn to Asp substitution, will have a greater reduction in cocaine use than those without this polymorphism. This hypothesis is based on the reduced rate of relapse during naltrexone treatment in alcoholic patients with this polymorphism compared to those without this polymorphism. The study will also explore several polymorphisms in the kappa and nociceptin/orphanin FQ neurotransmitter systems for their potential effects on treatment response to BUP/NTX based on protective associations of several of these polymorphisms with cocaine and other drug abuse.

    Node Involvement

    Lead Node(s):

  • Texas Node

  • All Participating Nodes:

  • New York Node
  • Ohio Valley Node
  • Pacific Northwest Node
  • Pacific Region Node
  • Southern Consortium Node
  • Western States Node